Monday's 7 Biggest Mid-Day Losers

shares 65.78 percent to $2.18 in pre-market trading after the company reported interim data from Wolverine Phase 2 trial of PNT2258 in diffuse large B-cell lymphoma (DLBCL). The company discontinued the development of DLBCL.

fell 53.61 percent to $4.11 in pre-market trading as the company revealed Monday it was advised by the FDA to expand its human study, as well as reliability student, i.e. product stress testing, to get its support for its NDA for Epinephrine injection. The medical regulator issued a complete response letter to it on Friday after the market closed.

shares fell 41.26 percent to $6.96 in pre-market trading after the company announced topline results from its second Phase 3 clinical trial evaluating the safety and efficacy of its DEXTENZA therapy. The company said its single primary endpoint, defined defined as the difference in the mean scores in ocular itching between the treatment group and the placebo comparator group at three time points 7 days following insertion of the depots, was not achieved.

shares dropped 40.98 percent to $10.83 after the company provided an update on its current clinical programs in patients with non-small cell lung cancer and other solid tumors.

shares declined 12.56 percent to $1.88 after surging 20.79 percent on Friday.

shares fell 9.28 percent to $15.84. JMP Securities downgraded Barracuda Networks from Market Perform to Market Underperform.

dropped 7 percent to $60.02. BB&T Capital downgraded Sturm Ruger from Buy to Hold.